Key result
Endothelin receptor antagonists show antiproteinuric effects in clinical trials and improve renal injury and fibrosis in experimental models of diabetic kidney disease.
Why the study?
Do endothelin receptor antagonists improve renal outcomes in patients with diabetic kidney disease?
Do endothelin receptor antagonists improve renal outcomes in patients with diabetic kidney disease?
Answers are grounded in this paper and cite their sources.
Endothelin receptor antagonists offer a promising therapeutic approach for diabetic kidney disease by reducing proteinuria and potentially slowing disease progression.
Diabetic kidney disease (DKD) remains the most common cause of chronic kidney disease and multiple therapeutic agents, primarily targeted at the renin-angiotensin system, have been assessed. Their only partial effectiveness in slowing down progression to end-stage renal disease, points out an evident need for additional effective therapies. In the context of diabetes, endothelin-1 (ET-1) has been implicated in vasoconstriction, renal injury, mesangial proliferation, glomerulosclerosis, fibrosis and inflammation, largely through activation of its endothelin A (ETA) receptor. Therefore, endothelin receptor antagonists have been proposed as potential drug targets. In experimental models of DKD, endothelin receptor antagonists have been described to improve renal injury and fibrosis, whereas clinical trials in DKD patients have shown an antiproteinuric effect. Currently, its renoprotective effect in a long-time clinical trial is being tested. This review focuses on the localization of endothelin receptors (ETA and ETB) within the kidney, as well as the ET-1 functions through them. In addition, we summarize the therapeutic benefit of endothelin receptor antagonists in experimental and human studies and the adverse effects that have been described.
No takes yet. Share an insight, caveat, or question.
Anguiano et al. (2015) conducted a review in Diabetic kidney disease. Endothelin receptor antagonists was evaluated. Endothelin receptor antagonists show antiproteinuric effects in clinical trials and improve renal injury and fibrosis in experimental models of diabetic kidney disease.
Synapse has enriched 10 related papers. Consider them for comparative context: